Adcetris gives Pfizer its first post-Seagen surprise
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.
MacroGenics muddies its key catalyst
Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?
Blenrep surprises again
After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.
Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
Pfizer takes multiple shots on goal
The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
